«Previous Article|Table of Contents|Next Article»

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:

2025 03

Page:

349-358

Research Field:

Publishing date:

Info

Title:

Key pathogenesis of B-cell lymphoma:Progress and prospect of BCR signaling pathway activation

Author(s):

GAO Zizhao¹; 2; 3; WANG Zhe¹; 2; 3

1.School of Basic Medicine,the Fourth Military Medical University,Shaanxi Xi'an 710032,China;2.Department of Pathology,Xijing Hospital,Shaanxi Xi'an 710032,China;3.State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers,Shaanxi Xi'an 710032,China.

Keywords:

lymphoma; B-cell receptor; targeted drug

PACS:

R733

DOI:

10.3969/j.issn.1672-4992.2025.03.001

Abstract:

B-cell lymphoma is the type of lymphoma with the highest incidence,in which most cases are mature B-cell lymphomas,and it has unique epidemiological,clinical pathological,and molecular genetic characteristics.Current research has found that B-cell receptor (BCR) signal transduction is a key pathway for tumor cell proliferation.However,the activation modes and degrees of BCR differ among different types of B-cell lymphoma,including viral/exogenous antigen stimulation,self-antigen stimulation,and mutations in relevant sites of the BCR pathway.At the same time,targeted drugs that target BCR pathway,such as Bruton tyrosine kinase (BTK),spleen tyrosine kinase (SYK),and phosphatidylinositol 3-kinase (PI3K) selectively inhibit BCR signaling,and these drugs can improve clinical outcomes of B-cell lymphoma.In this article,we will review the activation of BCR and related treatment in different types of B-cell lymphoma.

References:

£Û1£Ý KHOURY JD,SOLARY E,ABLA O,et al.The 5th edition of the World Health Organization classification of haematolymphoid tumours:myeloid and histiocytic/dendritic neoplasms£ÛJ£Ý.Leukemia,2022,36(7):1703-1719.
£Û2£Ý ZHANG F,LI W,ZHENG X,et al.The novel immune landscape of immune-checkpoint blockade in EBV-associated malignancies£ÛJ£Ý.FASEB Journal,2024,38(21):e70139.
£Û3£Ý BARMAN P,BASU S,GOYAL T,et al.Epstein-Barr virus-driven lymphoproliferation in inborn errors of immunity:a diagnostic and therapeutic challenge£ÛJ£Ý.Expert Review of Clinical Immunology,2024,20(11):1331-1346.
£Û4£Ý XU W,BERNING P,LENZ G.Targeting B-cell receptor and PI3K signaling in diffuse large B-cell lymphoma£ÛJ£Ý.Blood,2021,138(13):1110-1119.
£Û5£Ý STANCHINA MD,MONTOYA S,DANILOV AV,et al.Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia£ÛJ£Ý.Nature Reviews.Clinical Oncology,2024,21(12):867-887.
£Û6£Ý DONG Y,PI X,BARTELS-BURGAHN F,et al.Structural principles of B cell antigen receptor assembly£ÛJ£Ý.Nature,2022,612(7938):156-161.
£Û7£Ý KUTZNER K,WOODS S,KARAYEL O,et al.Phosphorylation of serine-893 in CARD11 suppresses the formation and activity of the CARD11-BCL10-MALT1 complex in T and B cells£ÛJ£Ý.Science Signaling,2022,15(723):eabk3083.
£Û8£Ý LI C,MORO S,SHOSTAK K,et al.Molecular mechanism of IKK catalytic dimer docking to NF-¦ÊB substrates£ÛJ£Ý.Nature Communications,2024,15(1):7692.
£Û9£Ý DO J,YENWONGFAI LN,DO SI,et al.Molecular complexity of diffuse large B-cell lymphoma:a molecular perspective and therapeutic implications£ÛJ£Ý.Journal of Applied Genetics,2024,65(1):57-72.
£Û10£Ý DO J,YENWONGFAI LN,DO SI,et al.Comparative study on the clinicopathologic and molecular characteristics of primary and secondary diffuse large B-cell lymphoma in the central nervous system£ÛJ£Ý.Journal of Applied Genetics,2024,44(7):2953-2960.
£Û11£Ý FISKE BE,WEMLINGER SM,CRUTE BW,et al.The Src-family kinase Lyn plays a critical role in establishing and maintaining B cell anergy by suppressing PI3K-dependent signaling£ÛJ/OL£Ý.bioRxiv:The Preprint Server for Biology,2024£Û2024-05-21£Ý.https://pubmed.ncbi.nlm.nih.gov/38826354/?sid_for_share=99125_3.DOI:10.1101/2024.05.21.595208.
£Û12£Ý KRAAN W,HORLINGS HM,VAN KEIMPEMA M,et al.High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites£ÛJ£Ý.Blood Cancer Journal,2013,3(9):e139.
£Û13£Ý ZHANG W,YANG P,YANG Y,et al.Genomic landscape and distinct molecular subtypes of primary testicular lymphoma£ÛJ£Ý.Journal of Translational Medicine,2024,22(1):414.
£Û14£Ý KRAAN W,VAN KEIMPEMA M,HORLINGS HM,et al.High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma£ÛJ£Ý.Leukemia,2014,28(3):719-720.
£Û15£Ý RIVAS-DELGADO A,L¦VPEZ C,CLOT G,et al.Testicular large B-cell lymphoma is genetically similar to PCNSL and distinct from nodal DLBCL£ÛJ£Ý.HemaSphere,2024,8(10):e70024.
£Û16£Ý SCHMITZ R,WRIGHT GW,HUANG DW,et al.Genetics and pathogenesis of diffuse large B-cell lymphoma£ÛJ£Ý.The New England Journal of Medicine,2018,378(15):1396-1407.
£Û17£Ý GERGELY L,UDVARDY M,ILLES A.The possible role of pathogens and chronic immune stimulation in the development of diffuse large B-cell lymphoma£ÛJ£Ý.Biomedicines,2024,12(3):648.
£Û18£Ý REDDY A,ZHANG J,DAVIS NS,et al.Genetic and functional drivers of diffuse large B cell lymphoma£ÛJ£Ý.Cell,2017,171(2):481-494.
£Û19£Ý LEE JH,JEONG H,CHOI JW,et al.Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma:a meta-analysis£ÛJ£Ý.Scientific Reports,2017,7(1):1785.
£Û20£Ý SHIMADA K,YOSHIDA K,SUZUKI Y,et al.Frequent genetic alterations in immune checkpoint-related genes in intravascular large B-cell lymphoma£ÛJ£Ý.Blood,2021,137(11):1491-1502.
£Û21£Ý CHEN Z,ZOU Y,LIU W,et al.Morphologic patterns and the correlation with MYD88 L265P,CD79B mutations in primary adrenal diffuse large B-cell lymphoma£ÛJ£Ý.The American Journal of Surgical Pathology,2020,44(4):444-455.
£Û22£Ý TANIGUCHI K,TAKATA K,CHUANG SS,et al.Frequent MYD88 L265P and CD79B mutations in primary breast diffuse large B-cell lymphoma£ÛJ£Ý.The American Journal of Surgical Pathology,2016,40(3):324-334.
£Û23£Ý FRANCO F,GONZALEZ-RINCON J,LAVERNIA J,et al.Mutational profile of primary breast diffuse large B-cell lymphoma£ÛJ£Ý.Oncotarget,2017,8(61):102888-102897.
£Û24£Ý LI P,CHAI J,CHEN Z,et al.Genomic mutation profile of primary gastrointestinal diffuse large B-cell lymphoma£ÛJ£Ý.Frontiers in Oncology,2021,11:622648.
£Û25£Ý OLLILA TA,OLSZEWSKI AJ.Extranodal diffuse large B cell lymphoma:molecular features,prognosis,and risk of central nervous system recurrence£ÛJ£Ý.Current Treatment Options in Oncology,2018,19(8):38.
£Û26£Ý FRICK M,BETTSTETTER M,BERTZ S,et al.Mutational frequencies of CD79B and MYD88 vary greatly between primary testicular DLBCL and gastrointestinal DLBCL£ÛJ£Ý.Leukemia & Lymphoma,2018,59(5):1260-1263.
£Û27£Ý TR¢hEN G,WARSAME A,DELABIE J.CD79B and MYD88 mutations in splenic marginal zone lymphoma£ÛJ£Ý.ISRN Oncology,2013,2013:1-4.
£Û28£Ý WANG JF,WANG Y,FENG C,et al.Epidemiology of marginal zone lymphoma£ÛJ£Ý.Annals of Lymphoma,2024,5:1.
£Û29£Ý ABABOU M,MAHTAT EM,JENNANE S,et al.Splenic marginal zone lymphoma associated with hepatitis B virus infection,remission after viral treatment,and splenectomy:A case report and review of the literature£ÛJ£Ý.Hematology/Oncology and Stem Cell Therapy,2021,14(2):153-155.
£Û30£Ý ABABOU M,MAHTAT EM,JENNANE S,et al.CD81 suppresses NF-¦ÊB signaling and is downregulated in hepatitis C virus expressing cells£ÛJ£Ý.Frontiers in Cellular and Infection Microbiology,2021,14:1338606.
£Û31£Ý FENG Y,DUAN TJ,HUANG Q,et al.The clinicopathological characteristics of gastric cancer and precancerous conditions in gastric DLBCL and MALT lymphoma patients:a multi-center retrospective study£ÛJ£Ý.Annals of Medicine,2023,55(1):2193423.
£Û32£Ý GHAFOURI AM,ALZAIDI S,AL-KAABI BB,et al.Thyroid B-cell lymphoma in the background of Hashimoto's thyroiditis:A case report and literature review£ÛJ£Ý.Cureus,2024,16(3):e57359.
£Û33£Ý MARTINEZ-LOPEZ A,CURIEL-OLMO S,MOLLEJO M,et al.MYD88 (L265P) somatic mutation in marginal zone B-cell lymphoma£ÛJ£Ý.American Journal of Surgical Pathology,2015,39(5):644-651.
£Û34£Ý ZHU D,IKPATT OF,DUBOVY SR,et al.Molecular and genomic aberrations in Chlamydophila psittaci negative ocular adnexal marginal zone lymphomas£ÛJ£Ý.American Journal of Hematology,2013,88(9):730-735.
£Û35£Ý GRAU M,L¢hPEZ C,NAVARRO A,et al.Unraveling the genetics of transformed splenic marginal zone lymphoma£ÛJ£Ý.Blood Advances,2023,7(14):3695-3709.
£Û36£Ý HUANG YJ,LIM JQ,HSU JS,et al.Next-generation integrated sequencing identifies poor prognostic factors in patients with MYD88-mutated chronic lymphocytic leukemia in Taiwan£ÛJ£Ý.Pathobiology,2024,33(5):1-13.
£Û37£Ý MALEKI Y,ALAHBAKHSHI Z,HEIDARI Z,et al.NOTCH1,SF3B1,MDM2 and MYD88 mutations in patients with chronic lymphocytic leukemia£ÛJ£Ý.Oncology Letters,2019,17(4):4016-4023.
£Û38£Ý SCHLETTE E,MEDEIROS LJ,KEATING M,et al.CD79b expression in chronic lymphocytic leukemia.Association with trisomy 12 and atypical immunophenotype£ÛJ£Ý.Archives of Pathology & Laboratory Medicine,2003,127(5):561-566.
£Û39£Ý ZHUANG X,YIN Q,YANG R,et al.Causal pathways in lymphoid leukemia:the gut microbiota,immune cells,and serum metabolites£ÛJ£Ý.Frontiers in Immunology,2024,15:1437869.
£Û40£Ý CHEN J,SATHIASEELAN V,REDDY CHILAMAKURI CS,et al.ZAP-70 augments tonic B-cell receptor and CCR7 signaling in IGHV-unmutated chronic lymphocytic leukemia£ÛJ£Ý.Blood Advances,2024,8(5):1167-1178.
£Û41£Ý SACHEN KL,STROHMAN MJ,SINGLETARY J,et al.Self-antigen recognition by follicular lymphoma B-cell receptors£ÛJ£Ý.Blood,2012,120(20):4182-4190.
£Û42£Ý CHA SC,QIN H,KANNAN S,et al.Nonstereotyped lymphoma B cell receptors recognize vimentin as a shared autoantigen£ÛJ£Ý.Journal of Immunology (Baltimore,Md.:1950),2013,190(9):4887-4898.
£Û43£Ý KRYSIAK K,GOMEZ F,WHITE BS,et al.Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma£ÛJ£Ý.Blood,2017,129(4):473-483.
£Û44£Ý GORDON MJ,SMITH MR,NASTOUPIL LJ.Follicular lymphoma:The long and winding road leading to your cure£ÛJ£Ý.Blood Reviews,2023,57:100992.
£Û45£Ý VARANO G,RAFFEL S,SORMANI M,et al.The B-cell receptor controls fitness of MYC-driven lymphoma cells via GSK3¦Â inhibition£ÛJ£Ý.Nature,2017,546(7657):302-306.
£Û46£Ý HE X,KL¦FSENER K,IYPE JM,et al.Continuous signaling of CD79b and CD19 is required for the fitness of Burkitt lymphoma B cells£ÛJ£Ý.The EMBO Journal,2018,37(11):e97980.
£Û47£Ý ABATE F,AMBROSIO MR,MUNDO L,et al.Distinct viral and mutational spectrum of endemic Burkitt lymphoma£ÛJ£Ý.PLOS Pathogens,2015,11(10):e1005158.
£Û48£Ý DONG LH,HUANG JJ,LIU J,et al.Expression of TCF3 in Burkitt's lymphoma and its proliferative effect and prognostic significance£ÛJ£Ý.Journal of Experimental Hematology,2022,30(5):1435-1439.
£Û49£Ý ZENG XX,GUO WW,SHEN J,et al.REG¦Ã promotes mantle cell lymphoma cell apoptosis by downregulating NF-¦ÊB signaling£ÛJ£Ý.Translational Cancer Research,2023,12(2):310-320.
£Û50£Ý SABA NS,LIU D,HERMAN SEM,et al.Pathogenic role of B-cell receptor signaling and canonical NF-¦ÊB activation in mantle cell lymphoma£ÛJ£Ý.Blood,2016,128(1):82-92.
£Û51£Ý WU C,DE MIRANDA NF,CHEN L,et al.Genetic heterogeneity in primary and relapsed mantle cell lymphomas:Impact of recurrent CARD11 mutations£ÛJ£Ý.Oncotarget,2016,7(25):38180-38190.
£Û52£Ý HILL HA,QI X,JAIN P,et al.Genetic mutations and features of mantle cell lymphoma:a systematic review and meta-analysis£ÛJ£Ý.Blood Advances,2020,4(13):2927-2938.
£Û53£Ý XOCHELLI A,SUTTON LA,AGATHANGELIDIS A,et al.Molecular evidence for antigen drive in the natural history of mantle cell lymphoma£ÛJ£Ý.The American Journal of Pathology,2015,185(6):1740-1748.
£Û54£Ý KAUR C,THAKUR A,LIOU KC,et al.Advances in the treatment of mantle cell lymphoma with BTK inhibitors£ÛJ£Ý.Leukemia Research,2024,147:107615.
£Û55£Ý KAUR C,THAKUR A,LIOU KC,et al.Spleen tyrosine kinase (SYK):an emerging target for the assemblage of small molecule antitumor agents£ÛJ£Ý.Leukemia Research,2024,33(9):897-914.
£Û56£Ý HIROKI H,AKAHANE K,INUKAI T,et al.Synergistic effect of combined PI3 kinase inhibitor and PARP inhibitor treatment on BCR/ABL1-positive acute lymphoblastic leukemia cells£ÛJ£Ý.International Journal of Hematology,2023,117(5):748-758.
£Û57£Ý BRAVO-GONZALEZ A,ALASFOUR M,SOONG D,et al.Advances in targeted therapy:addressing resistance to BTK inhibition in B-cell lymphoid malignancies£ÛJ£Ý.Trends in Pharmacological Sciences,2024,45(10):904-918.
£Û58£Ý BRAVO-GONZALEZ A,ALASFOUR M,SOONG D,et al.Targeted therapies in the treatment of mantle cell lymphoma£ÛJ£Ý.Cancers,2024,16(10):1937.
£Û59£Ý ASLAN B,MANYAM G,ILES LR,et al.Transcriptomic and proteomic differences in BTK-WT and BTK-mutated CLL and their changes during therapy with pirtobrutinib£ÛJ£Ý.Trends in Pharmacological Sciences,2024,8(17):4487-4501.
£Û60£Ý WANG JF,WANG Y,FENG C,et al.Protein-sequence-based search of nonreceptor ITAM-like regions to identify cytosolic Syk-recruiting proteins£ÛJ£Ý.Annals of Hematology,2024,128(40):9724-9733.
£Û61£Ý ADVANI RH,BUGGY JJ,SHARMAN JP,et al.Bruton tyrosine kinase inhibitor Ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies£ÛJ£Ý.Journal of Clinical Oncology,2013,31(1):88-94.
£Û62£Ý WALTER HS,RULE SA,DYER MJS,et al.A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies£ÛJ£Ý.Blood,2016,127(4):411-419.
£Û63£Ý BROWN JR,EICHHORST B,HILLMEN P,et al.Zanubrutinib or Ibrutinib in relapsed or refractory chronic lymphocytic leukemia£ÛJ£Ý.New England Journal of Medicine,2023,388(4):319-332.
£Û64£Ý BRADSHAW WJ,HARRIS G,GILEADI O,et al.The mechanism of allosteric activation of SYK kinase derived from multiple phospho-ITAM-bound structures£ÛJ£Ý.Structure,2024,32(12):2337-2351.
£Û65£Ý ANDORSKY DJ,KOLIBABA KS,ASSOULINE S,et al.An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphoma£ÛJ£Ý.British Journal of Haematology,2019,184(2):215-222.
£Û66£Ý AWAN FT,THIRMAN MJ,PATEL-DONNELLY D,et al.Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors:results of a phase 2 study£ÛJ£Ý.Leukemia & Lymphoma,2019,60(8):1972-1977.
£Û67£Ý WANG JF,WANG Y,FENG C,et al.Unveiling the role of PIK3R1 in cancer:A comprehensive review of regulatory signaling and therapeutic implications£ÛJ£Ý.Annals of Lymphoma,2024,106-107:58-86.
£Û68£Ý BROWN JR,BYRD JC,COUTRE SE,et al.Idelalisib,an inhibitor of phosphatidylinositol 3-kinase p110¦Ä,for relapsed/refractory chronic lymphocytic leukemia£ÛJ£Ý.Blood,2014,123(22):3390-3397.
£Û69£Ý MATASAR MJ,CAPRA M,¦ZZCAN M,et al.Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3):a double-blind,randomised,placebo-controlled,phase 3 trial£ÛJ£Ý.The Lancet Oncology,2021,22(5):678-689.
£Û70£Ý WANG JF,WANG Y,FENG C,et al.Six-year follow-up of phase II study exploring chemo-free treatment association with idelalisib and obinutuzumab in symptomatic relapsed/refractory patients with Waldenstr¢‰m's macroglobulinemia£ÛJ£Ý.Annals of Lymphoma,2024,32(11):33-41.
£Û71£Ý MATO AR,SHAH NN,JURCZAK W,et al.Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN):a phase 1/2 study£ÛJ£Ý.Lancet (London,England),2021,397(10277):892-901.

Memo

Memo:

-

Common functions

Last Update: 1900-01-01